What's hot

View all perspectives
      RT @EBRheum: Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA

      RTX not superior

      Mike Putman EBRheum

      3 years 10 months ago
      Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups Feel like this lends support to (~surprising) ACR/VF recs for EGPA? #ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
      RT @ericdeinmd: #ACR21 L19: TitAIN: Secukinumab for GCA
      ⭐️Phase 2 study with n=52
      ⭐️70% of SEC sustained remissi

      Eric Dein ericdeinmd

      3 years 10 months ago
      #ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnow https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
      RT @KDAO2011: IL-17i for GCA? TitAIN study met all endpoints!
      phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PC

      TheDaoIndex KDAO2011

      3 years 10 months ago
      IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
      RT @synovialjoints: Increased age at PSO diagnosis was significantly associated with shorter transition time between PSO

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Increased age at PSO diagnosis was significantly associated with shorter transition time between PSO and PsA diagnoses. No other variables, including BSA, were associated with time to transition @RheumNow #ACR21 Abst#1798 https://t.co/fLPBHKAMAc
      RT @uptoTate: Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #Rheum

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/TxyE4Uqttq https://t.co/Eykxwmcc44
      RT @drdavidliew: Secukinumab in GCA, phase 2 (TitAIN):
      I can't deny this is promising, but phase 2 needs to be

      interest

      David Liew drdavidliew

      3 years 10 months ago
      Secukinumab in GCA, phase 2 (TitAIN): I can't deny this is promising, but phase 2 needs to be interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def) @drpnash: "Bring on the phase 3 trials" (recruitment started👀) #ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ
      RT @ericdeinmd: #ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA
      ⭐️⬆️IFN in models of HLH/MAS, neutralization may

      Eric Dein ericdeinmd

      3 years 10 months ago
      #ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA ⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful ⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC ⭐️Ok to continue IL1i ▶️13/14 pts remission ▶️ SAEs: 1 CMV reactivation https://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC
      RT @bella_mehta: I am still obsessed with the name MAGIC syndrome -mouth and genital ulcers with inflamed cartilage!!
      1

      Bella Mehta bella_mehta

      3 years 10 months ago
      I am still obsessed with the name MAGIC syndrome -mouth and genital ulcers with inflamed cartilage!! 14% of patients with relapsing polychondritis have this! They also have features of aortitis, Raynaud's phenomenon and anticollagen II antibodies @rheumnow #ACR21 abt#1876 https://t.co/UlQUZlBPfx
      RT @bella_mehta: Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers

      Bella Mehta bella_mehta

      3 years 10 months ago
      Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062
      RT @Yuz6Yusof: #ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated M

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
      RT @Janetbirdope: What if a celebrity had #Scleroderma? Would that ⬆️attention & funding for this rare disease?

      Janet Pope Janetbirdope

      3 years 10 months ago
      What if a celebrity had #Scleroderma? Would that ⬆️attention & funding for this rare disease? See what Big Bird says @RheumNow #ACR21 ?affected #PetsofACR @RheumNow @scleroderma @SclerodermaCAN audio-13.m4a
      RT @ericdeinmd: #ACR21 L21. REOVAS: RTX for EGPA
      ⭐️CYC traditionally preferred for 5-factor score>0
      ▶️Remissi

      Eric Dein ericdeinmd

      3 years 10 months ago
      #ACR21 L21. REOVAS: RTX for EGPA ⭐️CYC traditionally preferred for 5-factor score>0 ▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction ▶️No diff in ANCA+/-, naive v relapse, FFS https://t.co/cuM9LcEr4u @Rheumnow
      RT @Janetbirdope: #Rituximab NOT different from conventional Rx in #eGPA #churgstrauss abst#L21 v small study, 60% ANCA

      Janet Pope Janetbirdope

      3 years 10 months ago
      #Rituximab NOT different from conventional Rx in #eGPA #churgstrauss abst#L21 v small study, 60% ANCA neg #ACR21 @RheumNow https://t.co/tO1vAF18y9
      Miss anything from Day 1? We are sharing the best #ACR21 abstracts from Day 1.

      https://t.co/YZ3jwW0Abu https://t.co/gv

      Dr. John Cush RheumNow

      3 years 10 months ago
      Miss anything from Day 1? We are sharing the best #ACR21 abstracts from Day 1. https://t.co/YZ3jwW0Abu https://t.co/gvWCrIbWuG
      Emapalumab (IFNg inhibitor) Effective in severe MAS (Ferritin 25K, failed anakinra, GC)- 14 pts (2-25 yrs; 4/14 sJIA)-13

      Dr. John Cush RheumNow

      3 years 10 months ago

      Emapalumab (IFNg inhibitor) Effective in severe MAS (Ferritin 25K, failed anakinra, GC)- 14 pts (2-25 yrs; 4/14 sJIA)-13/14 remission, w rapid drops in CXCL9, Ferritin, ALT, DDimers & GC dose #ACR21 ABst LB20 https://t.co/05oW5C8Waf https://t.co/ecEkt3MY83

      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×